Suppr超能文献

急性缺血性卒中的病理生理机制:一篇重点阐述溶栓以外治疗意义的综述

Pathophysiologic mechanisms of acute ischemic stroke: An overview with emphasis on therapeutic significance beyond thrombolysis.

作者信息

Deb Prabal, Sharma Suash, Hassan K M

机构信息

Department of Pathology, Armed Forces Medical College, Pune, India.

出版信息

Pathophysiology. 2010 Jun;17(3):197-218. doi: 10.1016/j.pathophys.2009.12.001. Epub 2010 Jan 13.

Abstract

Stroke is a serious neurological disease, and constitutes a major cause of death and disability throughout the world. The pathophysiology of stroke is complex, and involves excitotoxicity mechanisms, inflammatory pathways, oxidative damage, ionic imbalances, apoptosis, angiogenesis and neuroprotection. The ultimate result of ischemic cascade initiated by acute stroke is neuronal death along with an irreversible loss of neuronal function. Therapeutic strategies in stroke have been developed with two main aims: restoration of cerebral flow and the minimization of the deleterious effects of ischemia on neurons. Intense research spanning over the last two decades has witnessed significant therapeutic advances in the form of carotid endarterectomy, thrombolytics, anticoagulant therapy, antiplatelet agents, neuroprotective agents, and treating associated risk factors such as hypertension and hyperlipidemia. However, the search for an effective neuroprotectant remains frustrating, and the current therapeutic protocols remain suboptimal. Till date only one FDA-approved drug is available for ischemic stroke; i.e., the serine protease tissue-type plasminogen activator (tPA), utility of which is limited by short therapeutic window. The objective of this review is to critically evaluate the major mechanisms underlying stroke pathophysiology, with emphasis on potential novel targets for designing newer therapeutic modalities.

摘要

中风是一种严重的神经疾病,是全球死亡和残疾的主要原因之一。中风的病理生理学很复杂,涉及兴奋毒性机制、炎症途径、氧化损伤、离子失衡、细胞凋亡、血管生成和神经保护。急性中风引发的缺血级联反应的最终结果是神经元死亡以及神经元功能的不可逆丧失。中风的治疗策略主要有两个目标:恢复脑血流并将缺血对神经元的有害影响降至最低。在过去二十年中进行的大量研究见证了以颈动脉内膜切除术、溶栓剂、抗凝治疗、抗血小板药物、神经保护剂以及治疗高血压和高脂血症等相关危险因素等形式取得的重大治疗进展。然而,寻找一种有效的神经保护剂仍然令人沮丧,目前的治疗方案仍然不尽人意。迄今为止,缺血性中风只有一种获得美国食品药品监督管理局(FDA)批准的药物,即丝氨酸蛋白酶组织型纤溶酶原激活剂(tPA),其效用受限于较短的治疗窗口。本综述的目的是批判性地评估中风病理生理学的主要机制,重点是设计更新治疗方式的潜在新靶点。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验